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ttp://dx.doi.org/10.1016/j.ajpath.2014.05.008Impairment of tissue ﬂuid homeostasis and migration of inﬂammatory cells across the vascular endothelial
barrier are crucial factors in the pathogenesis of acute lung injury (ALI). The goal for treatment of ALI is to
target pathways that lead to profound dysregulation of the lung endothelial barrier. Although studies have
shown that chemical epigenetic modiﬁers can limit lung inﬂammation in experimental ALI models, studies
to date have not examined efﬁcacy of a combination of DNA methyl transferase inhibitor 5-Aza 2-
deoxycytidine and histone deacetylase inhibitor trichostatin A (herein referred to as AzaþTSA) after
endotoxemia-induced mouse lung injury. We tested the hypothesis that treatment with AzaþTSA after
lipopolysaccharide induction of ALI through epigenetic modiﬁcation of lung endothelial cells prevents
inﬂammatory lung injury. Combinatorial treatment with AzaþTSA mitigated the increased endothelial
permeability response after lipopolysaccharide challenge. In addition, we observed reduced lung inﬂam-
mation and lung injury. AzaþTSA also signiﬁcantly reduced mortality in the ALI model. The protection was
ascribed to inhibition of the eNOS-Cav1-MLC2 signaling pathway and enhanced acetylation of histone
markers on the vascular endothelial-cadherin promoter. In summary, these data show for the ﬁrst time the
efﬁcacy of combinatorial AzaþTSA therapy in preventing ALI in lipopolysaccharide-induced endotoxemia
and raise the possibility of an essential role of DNA methyl transferase and histone deacetylase in the
mechanism of ALI. (Am J Pathol 2014, 184: 2237e2249; http://dx.doi.org/10.1016/j.ajpath.2014.05.008)Supported in part by American Heart Association granteJon Holden
DeHaan Foundation grant 10SDG2630181, and NIH-supported clinical and
translational science award Frontiers Pilot grant (J.R.), and NIH grants
R21HL97349 (J.R.) and R01 HL-117730 (B.D.).
Disclosures: None declared.Sepsis-induced acute lung injury (ALI) is an inﬂammatory
disorder that affects 18 million people worldwide and 200,000
people in theUnited States each year1,2 and is associatedwith a
mortality rate of approximately 30% despite advanced inter-
ventions.3e5 Sepsis is a primary pathogenic factor. It induces
progressive respiratory failure with bilateral alveolar inﬁltrates
and protein-rich lung edema ﬂuid secondary to severe
disruption of the lung vascular endothelial barrier.6 Although
antibiotics and volume replacement are the cornerstones of
current therapy in sepsis,7 an unchecked inﬂammatory
response limits their effectiveness. Therapies based on a new
understanding of the disease pathogenesis are needed.
DNA methylation and histone deacetylation are frequent
epigenetic events that dictate gene expression and cellular
fate.8,9 We selected DNAmethyl transferase inhibitor (5-Azastigative Pathology.
.2-deoxycytidine; Aza) and histone deacetylase (HDAC) in-
hibitor (trichostatin A; TSA) for several reasons, as follows:
i) both types of inhibitors have well-established biological
activities; ii) Aza is approved by the U.S. Food and Drug
Administration and has the potential to be re-purposed10,11;
and iii) both reagents have well-documented safety and side
effect proﬁles.12,13 We decided to use the epigenetic modiﬁer
Aza because it incorporates into DNACpG sites opposite to a
methylated CpG site, thereby inhibiting the DNA methyl
Thangavel et altransferase enzyme action in the DNA. This inhibition causes
loss of DNA methylation in one daughter DNA strand,
because DNA methyl transferase is not available to reme-
thylate the hemi-methylated sites generated during the ﬁrst
round of DNA replication.10,14 We decided to use TSA
because it is a potent general inhibitor of HDACs, which
chelates the center zinc ﬁnger of the HDACs, thereby
inhibiting enzyme activity.15,16 Acetylated histone is gener-
ally thought to act as an on-switch for DNA transcription.
Treating cells with TSA results in acetylation of H3 and H4,
thereby counteracting the tendency for nuclear compaction,
and making the DNA more accessible for interaction with
transcription factors.17,18 TSA and TSA-related reagent
suberoylanilide hydroxamic acid also appear to have rela-
tively short-lived effects on histone acetylation in vivo,19
suggesting that they may not cause permanent genetic
changes. In humans, oral suberoylanilide hydroxamic acid
induced rapid acetylation of histones in blood within 2 hours,
with return to baseline within 8 hours.19 Moreover, TSA
improved survival in models of hemorrhagic shock in rodents
and swine.20 We postulated that exposure to AzaþTSA with
the consequent epigenetic changes will transiently reactivate
the vascular endothelial (VE)-cadherin genes that are
silenced by lipopolysaccharide (LPS).
Loss of endothelial barrier plays an important role in
passage of plasma proteins into lung tissue, leading to
accumulation of protein-rich edema21,22 and transmigration
of neutrophils.23,24 Studies have shown that endothelial
nitric-oxide synthase (eNOS)-mediated nitric oxide (NO)
production plays an important role in regulating vascular
function and pathophysiology.25 Studies have also reported
that caveolin1 (Cav1), the protein associated with caveolae in
endothelial cells,26 functions as an endogenous negative
regulator of eNOS activity and is held in an inactive state
through direct interaction.26e28 These ﬁndings were corrob-
orated by our recent study showing that diminished Cav1-
eNOS interaction enhanced nitration-mediated inactivation
of p190RhoGAP-A, thus increasing vascular permeability.29
In this study, we tested the hypothesis that treatment with
AzaþTSA after LPS induction of ALI through epigenetic
modiﬁcation of lung endothelial cells prevents inﬂammatory
lung injury. Our studies were focused on lung endothelial
cells because of their role in orchestrating lung inﬂammation
and injury.30,31 We showed the critical role of epigenetic
modiﬁers AzaþTSA in preventing lung vascular hyper-
permeability and ALI.
Materials and Methods
Antibodies and Reagents
We used antibodies for phospho-eNOS-Ser1177, myosin light
chain 2 (MLC2), phospho-MLC2-Thr18/Ser19, caspase 3
(Cell Signaling Technology, Danvers, MA), VE-cadherin,
eNOS, p-eNOS, b-actin, Cav1, and p-Cav1 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) and Ly-6G6C antibody2238for neutrophils (Novus Biological, Littleton, CO). Secondary
antibodies were horseradish peroxidaseeconjugated donkey
anti-mouse, anti-rabbit, and anti-goat (Santa Cruz Biotech-
nology, Inc.); tetramethylrhodamine isothiocyanatee and
ﬂuorescein isothiocyanateeconjugated donkey anti-mouse,
anti-goat, and anti-rabbit (Jackson ImmunoResearch Labo-
ratories, Inc., West Grove, PA), and DAPI (Life Technolo-
gies, Carlsbad, CA); antibodies eNOS, VE-cadherin, CD31
(eBioscience, San Diego, CA), and L-NG-nitroarginine
methyl ester (L-NAME; Calbiochem, San Diego, CA).
Mice
Male C57BL/6 mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). All experiments were con-
ducted in accordance with the NIH’s Guide for the Care and
Use of Laboratory Animals32 and were approved by the
Institutional Animal Care and Use Committee of the Uni-
versity of Illinois at Chicago (Chicago, IL). All experiments
were performed with 8- to 10-week-old mice.
Primary MLEC Culture
Primary culture of mouse lung endothelial cells (MLECs) was
performed with cells immunoselected from mouse lungs as
previously described.33 Brieﬂy, a cell suspensionwas prepared
from lungs by digestion with 1 mg/mL collagenase II and 0.5
mg/mL dispase for 30 minutes twice, followed by ﬁltration
with 70-mm and 40-mm nylon ﬁlters. Endothelial cells were
then selected with a rat antibody to mouse CD31 (Millipore,
Billerica, MA) and a secondary antibody coupled to magnetic
beads (Miltenyi Biotec, Bergisch Gladbach, Germany). Puri-
ﬁed endothelial cells were plated on 0.1% gelatin-coated six-
well plates for 7 days in the complete EBM-2medium (Lonza,
Basel, Switzerland). The cells were stained with CD31 surface
expression for ﬂow cytometric analysis. The mRNA expres-
sions of CD31, VE-cadherin, and vascular cell adhesion
molecule 1 (VCAM1)weremeasured by quantitative real-time
RT-PCR (RT-qPCR). Primary cultures of MLECs at passages
4 to 10 were used for all of the experiments. The phase-
contrast microscopic image was taken to show the cobble-
stone pattern and elongated endothelial morphology of cells
identiﬁed as endothelial cells. These primary MLECs were
used for all of our in vitro experiments.
Cell Viability and Proliferation Assays
The in vitro viability and proliferation of the AzaþTSA-
treated primary MLECs were evaluated by Trypan blue
exclusion and MTT cell proliferation assays, respectively, as
described by us earlier.34 Brieﬂy, MLECs were cultured with
different concentrations of Aza and TSA in 12-well culture
plates for 48 or 72 hours (Supplemental Figure S1), cells were
harvested and exposed to Trypan blue solution (ﬁnal con-
centration 0.1%), and the number of viable (unstained) and
nonviable (stained) cells was counted with a hemocytometer.ajp.amjpathol.org - The American Journal of Pathology
Attenuation of Lung HyperpermeabilityThe effect of AzaþTSA on MLEC proliferation was deter-
mined by MTT assay according to the manufacturer’s in-
structions (Cell Proliferation Assay kit; Promega, Madison,
WI). Brieﬂy, 104 MLECs were cultured in 96-well culture
plate (200 mL per well) in Dulbecco’s modiﬁed Eagle’s me-
dium that contained 10% fetal bovine serum in the presence
and absence of various concentrations of AzaþTSA for 48
hours at 37C at 5% CO2. MTT assay results were conﬁrmed
by manual counting under the phase-contrast microscope.
Flow Cytometric Analysis
Cells from a 6-well plate were harvested and washed twice in
phosphate-buffered saline (PBS), counted, and resuspended in
ﬂuorescence-activated cell sorting buffer (1% bovine serum
albumin in PBS that contained 0.01% NaN3). For ﬂow cyto-
metric phenotype analysis, 1  106 cells were initially incu-
bated with 10% mouse serum for 20 minutes at 4C.
Subsequently, cells were incubated with the appropriately
labeled primary antibodies for 1 hour. Then the cells were
washed with washing buffer three times and incubated for 20
minutes with the use of an appropriate secondary antibody. All
incubations were performed on ice. Appropriate isotype con-
trols were used in all cases. Finally, the cells werewashed three
times with ﬂuorescence-activated cell sorting buffer, resus-
pended in 0.5 mL of PBS, and analyzed by ﬂow cytometry
(FACSCalibur version 2.0; BD Biosciences, San Jose, CA)
with the use of Cell Quest software. Data were analyzed with
the FlowJo software version 7 (TreeStar, Ashland, OR). Pri-
mary antibodies anti-CD31 for characterization of endothelial
cells and anti-caspase 3 for apoptosis were used.
RT-qPCR
LPS-induced treated cells with AzaþTSA and untreated
cells and normal cells from a six-well plate were washed
once in PBS and harvested for RT-qPCR analysis as
described by us earlier.34,35 Brieﬂy, total cellular RNA was
obtained for RT-qPCR analysis to determine mRNA
expression of endothelial markers CD31, VE-cadherin, and
VCAM1 and cytokine inﬂammatory markers tumor necro-
sis factor a (TNFa) and IL-8. RT-qPCR analysis was per-
formed on ViiA 7 (Life Technologies) with gene-speciﬁc
primers and SYBRGreenMaster Mix (eBioscience). Primer
sequences used for the RT-qPCR analysis were as follows:
CD31 forward (50-TCCCCGAAGCAGCACTCTT-30) and
reverse (50-ACCGCAATGAGCCCTTTCT-30), VE-cadherin
forward (50-GTGGATGAGCCCCCTGTCT-30) and reverse
(50-CAGCGGTTTCTTCTCGTTTTCT-30), VCAM1 forward
(50-CATGGAATTCGAACCCAAACA-30) and reverse (50-
GGCTGACCAAGACGGTTGTATC-30), IL8 forward (50-
TGTCCCCAAGTAACGGAGAAA-30) and reverse (50-
TGTCAGAAGCCAGCGTTCAC-30), and TNFa forward (50-
GGCTGCCCCGACTACGT-30) and reverse (50-AGGTT-
GACTTTCTCCTGGTATGAGA-30). The relative mRNA
expression of target genes was normalized to endogenous 18SThe American Journal of Pathology - ajp.amjpathol.orgcontrol gene (Applied Biosystems, Foster City, CA). Results
were expressed as fold change in expression, and values were
calculated as the ratio of induced expression to control
expression.
Western Blot Analysis
Immunoprecipitation and Western blot analyses of VE-
cadherin, caspase 3, p-eNOS, p-Cav1, and p-MLC2 proteins
were performed as described earlier.34 Brieﬂy, 5  106 pri-
mary MLECs per lane were cultured in complete Dulbecco’s
modiﬁed Eagle’s medium in the presence and absence of 1 mg/
mL LPS and immediately treated with 50 nm of Aza, 25 nmol/
L TSA, or a combination of both Aza and TSA for 30 minutes
for phosphorylated proteins and 24 hours for non-
phosphorylated proteins at 37C. The cells were then washed
in ice-cold PBS and solubilized by gentle rocking in 100 mL of
lysis buffer. Endothelial lung cell lysates or immunoprecipi-
tates were resolved by SDS-PAGE on a 4% to 12% gradient or
10% separating gel under reducing conditions and transferred
toDuralosemembrane.Membranes were blocked with 5%dry
milk in 10 mmol/L Tris-HCl, pH 7.5, 150 mmol/L NaCl, and
0.05% Tween 20 for 1 hour. Membranes were then incubated
with the indicated primary antibody (diluted in blocking
buffer) overnight. All primary antibodies were used at the
dilution of 1:1000. After three washes, membranes were
incubated with horseradish peroxidaseeconjugated goat anti-
rabbit ormouse antibody. Protein bandswere detectedwith the
enhanced chemiluminescence method.
Immunoﬂuorescence Staining
Protein expression was evaluated by immunoﬂuorescence
staining as described earlier.34,35 Brieﬂy, cultured cells and
lung tissue were rinsed once with PBS and ﬁxed with 4%
paraformaldehyde (Sigma-Aldrich, St. Louis, MO) in PBS
for 5 minutes, then rinsed three times with PBS, per-
meabilized with 0.3% Triton X-100 (Sigma-Aldrich) in PBS
for 3 minutes, washed twice with PBS, and incubated over-
night at 4C with primary antibodies (eNOS, VE-cadherin,
caspase 3) diluted with 2% bovine serum albumin in PBS.
After three washes with PBS, cells were incubated with
speciﬁc secondary antibodies for 1 hour at 37C, and cells
were rinsed three times with PBS, stained with DAPI to
visualize cell nuclei, rinsed three times with PBS, air dried,
and mounted in Vectashield mounting medium for ﬂuores-
cent imaging. All immunoﬂuorescence staining images were
captured with either a confocal or an immunoﬂuorescence
microscope.
ChIP Assay
Chromatin immunoprecipitation (ChIP) assays for the
VE-cadherin promoter region in LPS-induced MLECs
treated or untreated with Aza alone, TSA alone, or
AzaþTSA were performed according to the manufacturer’s2239
Thangavel et alprotocol (Millipore), also described in our recent publica-
tion.34,35 Brieﬂy, approximately 5  106 cells in two 10-cm
culture plates for each sample were incubated with 1%
formaldehyde diluted in culture medium for 10 minutes at
37C. The samples were then lyzed in SDS lysis buffer that
contained protease inhibitors (1 mmol/L phenyl-
methylsulfonyl ﬂuoride, 1 mg/mL aprotinin, and 1 mg/mL
pepstatin A). Next, the samples were sonicated on ice to
shear DNA to lengths between 200 and 1000 bp and incu-
bated with primary antibodies to acetylated histone 3 lysine
(aceH3K9, aceH3K18) and dimethylated histone 3 lysine 9
(me2H3K9; Millipore) overnight at 4C on a shaker plate.
Then samples were incubated with Salmon Sperm DNA/
Protein A agarose slurry for 1 hour at 4C on a shaker plate.
After four washes with washing buffers, the pelleted protein
A agarose/antibody/histone complex was incubated with
elution buffer (1% SDS and 0.1 mol/L NaHCO3) for 15
minutes at room temperature. Then the samples were incu-
bated with 0.2 mol/L NaCl for 4 hours at 65C. After DNA
was recovered by phenol/chloroform extraction and ethanol
precipitation, PCR was performed with VE-cadherin pro-
moter forward (50-CACCGCAGGGCCTGCCTAT-30) and
reverse (50-TGTCAGCCGACCGTCTTTGGA-30) primers.
Aliquots of samples before immunoprecipitation (input)
were analyzed by PCR to quantify the amount of DNA
present in different samples. The relative DNA levels in
each sample were normalized to its input DNA levels.34,35
Induction of ALI
ALI was induced in C57BL/6J mice by intraperitoneal injec-
tion of a lethal dose of LPS [40mg/kg bodyweight (BW)].One
hour after LPSadministration, themice received treatmentwith
vehicle or Aza (4.4 mmol/L/kg BW) or TSA (3.3 mmol/L/kg
BW) or AzaþTSA. Survival was monitored for 14 days. For
histological, gene expression, and cytokine assays, the mice
received a single sublethal dose of LPS (10mg/kgBW; Sigma-
Aldrich) intraperitoneally. One hour after LPS challenge, the
mice were treated intraperitoneally with either 4.4 mmol/L/kg
BWAzaþ 3.3mmol/L/kgBWTSAor 4.4mmol/L/kgBWAza
alone or 3.3 mmol/L/kgBWTSAalone.Micewere euthanized,
andhistological changes andgeneexpressionwere evaluated in
the lung tissues on day 2. To avoid sampling bias during the
processing of lung tissue sections and tissue for lung endo-
thelial cells in culture, we followed the systematic uniform
random sampling method. An initial random cut was made
through the lung, followed by serial parallel slices made at a
constant thickness interval. The slices were ﬂipped 90 degrees
in the same direction as described earlier.36
Pulmonary Microvascular Permeability
Pulmonary microvascular permeability to liquid was quanti-
ﬁed by measuring capillary ﬁltration coefﬁcient (Kfc) as pre-
viously described.37 Brieﬂy, mice received a single sublethal
dose of LPS (10mg/kgBW;Sigma-Aldrich) intraperitoneally.2240One hour after LPS challenge, the mice were treated intra-
peritoneally with either 4.4 mmol/L/kg Aza þ 3.3 mmol/L/kg
TSAor 4.4mmol/L/kgAza alone or 3.3mmol/L/kgTSAalone.
Mice were euthanized at 6 hours after LPS administration, and
lungs were dissected free of nonpulmonary tissue, and dry
weight was determined. Kfc (mL/minute/cm H2O/dry g) was
calculated from the slope of the recorded weight change
normalized to the pressure change and to lung dry weight.
Trans-Endothelial Electrical Resistance Assay
Real-time changes in resistance of the endothelial mono-
layer were measured in vitro to assess endothelial cell
hyperpermeability and adherens junction (AJ) integrity as
previously described.37 In brief, MLECs from C57/BL6
mice were grown to conﬂuence on polycarbonate wells that
contained a small gold electrode (4.9  104 cm2). Before the
experiment, the conﬂuent MLEC monolayer was kept in
medium that contained 1% fetal bovine serum for 2 hours.
Then LPS, followed by Aza alone or TSA alone or
AzaþTSA, was added in the culture at different time points,
and resistance over the MLEC monolayer was monitored.
The data were subsequently presented as absolute values.
Myeloperoxidase Assay
Lung tissues were homogenized in 5 mmol/L phosphate
buffer and then centrifuged at 16,200  g (Sorvall Legend
Micro 17R centrifuge; Thermo Electron LED GmbH,
Osterode, Germany) for 20 minutes at 4C. The pellets were
resuspended in PBS that contained 0.5% hexadecyl trime-
thylammonium bromide and were subjected to a cycle of
freezing and thawing. Subsequently, the pellets were ho-
mogenized, and the homogenates were centrifuged again.
The supernatants were assayed for myeloperoxidase activity
by using kinetics readings for 3 minutes, and absorbance
was measured at 460 nm. The results were presented as
DOD460/minute/g lung tissue.38
TUNEL Assay
To assess the survival of lung cells and the effects of
AzaþTSA on survival of lung tissues, we performed an
apoptosis assay on lung tissue collected on day 6. Cell death
was assessed with the terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labeling (TUNEL) kit according to
the manufacturer’s instructions (Roche Applied Science,
Indianapolis, IN). After TUNEL assay staining, sections
were examined by confocal microscopy.
Statistical Analysis
All experiments were performed at least three times. Results
are presented as means  SEM. Comparisons were per-
formed by analysis of variance (GB-STAT version 10; Dy-
namic Microsystems, Silver Spring, MD) or c2 test forajp.amjpathol.org - The American Journal of Pathology
Figure 1 Assessment of Aza and TSA on lung endothelial viability and proliferation assays. Viability of MLECs after treatment with Aza and TSA as
evaluated with Trypan blue dye exclusion assay. A: Treatment with up to 50 nmol/L Aza and 25 nmol/L TSA has no signiﬁcant effect on cell viability. B:
Proliferative effect of Aza and TSA on MLECs as determined by MTT assay. C: Cell proliferation by hemocytometer cell counting for 48 hours. Data are expressed
as means  SEM. n Z 3; numbers within the parentheses indicate the concentration in nanomolar. *P < 0.05 versus control. A, Aza; T, TSA.
Attenuation of Lung Hyperpermeabilitypercentages. All tests were two-sided, and P < 0.05 was
considered statistically signiﬁcant. Survival between the
intervention and control groups was compared with the log-
rank test.
Results
AzaþTSA Treatment Does Not Affect Cell Viability
To examine toxicity of the epigenetic modiﬁers Aza and TSA
used in this study, we performed in vitro viability and prolif-
erative studies on primary MLECs. MLECs were cultured withFigure 2 AzaþTSA treatment reduces lung endothelial cell apoptosis and inc
caspase 3 (green), VE-cadherin (red), and nuclear staining DAPI (blue). B: Quant
LPS-induced MLECs treated with AzaþTSA compared with untreated MLECs or MLE
AzaþTSA treatment reduces expression of cleaved caspase 3 activity. MLECs were e
nmol/L Aza or 25 nmol/L TSA or AzaþTSA. After treatment for 24 hours, cells were
caspase 3 are shown. The combinatorial treatment with AzaþTSA inhibits the LPS-
Protein quantiﬁcation as assessed by densitometry. Data are expressed as means 
LPSþTSA. Original magniﬁcation: 400 (A). A, Aza; L, LPS; T, TSA.
The American Journal of Pathology - ajp.amjpathol.orgdifferent concentrations of Aza and TSA in 12-well culture
plates for 48 or 72 hours33 (Supplemental Figure S1), and then
cells were harvested and exposed to Trypan blue solution (ﬁnal
concentration 0.1%), and the number of viable (unstained) and
nonviable (stained) cells was counted in a hemocytometer.
Treatment with up to 50 nmol/L Aza and 25 nmol/L TSA had
no signiﬁcant effect on cell viability (Figure 1A). AzaþTSA-
treated MLECs showed normal ability to proliferate in MTT
assay (P < 0.05) (Figure 1B). This ﬁnding was further
corroborated by manual cell counting under the microscope
(P < 0.05) (Figure 1C). Thus, our observations suggested that
treatment with up to 50 nmol/LAza and 25 nmol/L TSA had noreases cell survival after LPS exposure. A: Immunoﬂuorescence staining of
iﬁcation of caspase 3-positive cells shows fewer caspase 3-positive cells in
Cs treated with either Aza alone or TSA alone after 24 hours of culture. C:
xposed to 1 mg/mL LPS in the presence or absence of an optimal dose of 50
harvested for Western blot analysis; representative Western blots for cleaved
induced increase in cleaved caspase 3; b-actin was used as loading control.
SEM. nZ 3. **P < 0.01 LPS versus LPSþAzaþTSA; yP < 0.05 LPS versus
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Figure 3 Treatment with AzaþTSA prevents LPS-induced lung vascular
hyperpermeability determined by vascular Kfc. A: Untreated LPS-induced
lungs show higher Kfc at 6 hours, whereas the AzaþTSA-treated lungs
show signiﬁcantly lower Kfc than the untreated LPS control lungs. B: TER of
primary MLECs exposed to 1 mg/mL LPS for 4 hours followed by treatment
with AzaþTSA or 50 nmol/L Aza alone or 25 nmol/L TSA alone for 3 hours.
Data are expressed as means  SEM (A). *P < 0.05 LPS versus
LPSþAzaþTSA (A); yP < 0.01 control LPS versus LPSþAzaþTSA (B).
Thangavel et altoxic effect on cell viability; rather, it increased cell proliferation
(Figure 1C). On the basis of these data, we further used con-
centrations of 50 nmol/L Aza and 25 nmol/L TSA in all of our
in vitro experiments.
AzaþTSA Treatment Reduces LPS-Induced Endothelial
Cell Apoptosis by Reducing Caspase 3 Activity and
Promotes Cell Survival
Caspases are cysteine proteases, which play essential roles in
apoptosis, necrosis, and inﬂammation. To examine whether
AzaþTSA exerts anti-apoptotic actions on LPS-exposed
MLECs, we performed caspase 3 staining as described by
the manufacturer’s instructions (Invitrogen, Eugene, OR) for
ﬂow cytometric analysis. Primary MLECs were cultured
(Supplemental Figure S1) and treated with AzaþTSA in the
presence and absence of 1 mg/mL LPS for 24 hours. The ﬂow
cytometric analysis showed that in the control (untreated)
group, 0.6% of cells were positive for caspase 3, and the
percentage of caspase 3-positive cells increased signiﬁcantly
to 85.3% in LPS-inducedMLECs (Supplemental Figure S2, A
and B). This LPS-induced increase in caspase 3 positivity was
signiﬁcantly reduced (64.3%) in MLECs treated with
AzaþTSA compared with either Aza alone or TSA alone
(85.3% versus 64.3%, respectively; P < 0.05) (Supplemental
Figure S2, A and B). This ﬁnding was further corroborated by
immunoﬂuorescence staining for caspase 3 and VE-cadherin
and by Western blot analysis for caspase 3 cleavage and ac-
tivity. The immunoﬂuorescence staining (Figure 2A) and
quantitative data (Figure 2B) showed that under high-
magniﬁcation visual ﬁeld of the immunoﬂuorescence micro-
scope, 30  5 cells stained positive for caspase 3 when the
cells were exposed to LPS. After treatment with AzaþTSA,
the number of MLECs positive for caspase 3 per high-
magniﬁcation visual ﬁeld decreased signiﬁcantly to 5  2,
whereas 27 4 and 22 4 cells per high-magniﬁcation visual
ﬁeld were positive for caspase 3 in cells treated with Aza alone
or TSA alone, respectively (P < 0.01) (Figure 2, A and B).
Data from Western blot analysis further conﬁrmed that
combinatorial treatment with AzaþTSA inhibited the LPS-
induced increase in caspase 3 activity (P < 0.01) to a greater
extent compared with cells treated with either Aza or TSA
alone (P< 0.05) (Figure 2C). Overall, these data indicated that
LPS increases cleaved caspase 3 activity, committing MLECs
toward apoptosis, whereas treatment with AzaþTSA reduced
the increased cleaved caspase 3 activity, suggesting its role in
apoptosis prevention and increased survival.
AzaþTSA Treatment Prevents LPS-Induced Lung
Vascular Hyperpermeability
We quantiﬁed alterations in lung microvascular permeability
by Kfc, as described earlier.
37 Mice were exposed to a sub-
lethal dose of LPS (10 mg/kg BW) followed by intraperito-
neal treatment with either AzaþTSA or 4.4 mmol/L/kg Aza
alone or 3.3 mmol/L/kg TSA alone. In untreated mice, LPS2242exposure resulted in a signiﬁcant increase in lung micro-
vascular permeability compared with basal condition
(Figure 3A). Strikingly, this increase in Kfc was signiﬁcantly
inhibited in mice treated with AzaþTSA (0.0587  0.018 in
the LPS-exposed group versus 0.029  0.011 in the LPS-
exposed mice treated with AzaþTSA; P < 0.01)
(Figure 3A) rather than either alone.
To conﬁrm our ﬁndings in vivo and to elucidate the
mechanisms of AzaþTSA-mediated endothelial barrier
protection, we studied alterations in endothelial cell junc-
tions, crucial for the maintenance of barrier integrity. We
used an in vitro culture system of conﬂuent MLEC mono-
layer and measured trans-endothelial electrical resistance
(TER), which provides an assessment of junction alterations
as described earlier.37 At 4 hours after drug treatment, all of
the four groups of MLEC monolayers exhibited similar
basal barrier function assessed by TER (Figure 3B).
Monolayers were then challenged with 1 mg/mL LPS, and
changes were monitored for 3 hours. We observed similar
decreases of TER in response to LPS in all groups except the
AzaþTSA-treated group (P < 0.01) (Figure 3B). This
ﬁnding indicated that AzaþTSA treatment ameliorates
LPS-induced endothelial barrier disruption. Overall, these
data indicated that AzaþTSA has a protective role inajp.amjpathol.org - The American Journal of Pathology
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endothelial barrier disruption in LPS-induced lung injury.
AzaþTSA in Combination Protects AJ Integrity in
Endothelial Cells
To elucidate the mechanism of restoration of microvascular
endothelial barrier function and AJ integrity during ALI,
MLECs were cultured to conﬂuence and stimulated with
LPS, followed by treatment with either AzaþTSA or Aza
alone or TSA alone for 24 hours. Next, cells were analyzed
for VE-cadherin and activated eNOS protein by Western
blot, RT-qPCR, and immunoﬂuorescence analyses. With
the use of confocal microscopy, we observed that, in control
MLECs, VE-cadherin localized primarily at the cell borders
and had a more jagged or zigzag appearance with mainte-
nance of normal AJ integrity (Figure 4A). Neighboring cells
were generally connected by interdigitating ﬁnger-like
grooves, which stained positively for VE-cadherin. These
structures appeared greatly exaggerated in LPS-inducedFigure 4 Treatment with AzaþTSA prevents LPS-induced loss of vascular AJ int
by treatment with either AzaþTSA or Aza alone or TSA alone for 24 hours. A: Re
labeled eNOS as detected by immunoﬂuorescence staining. In AJ, VE-cadherin sh
tween the cell borders (white arrows). In LPS-induced MLECs, treatment with Aza
with jagged or zigzag appearance and more prominent AJs similar to unstimulate
increases in MLECs exposed to LPS and treated with AzaþTSA than either Aza alon
experimental cell expression to expression in control cells. C: Protein expression of
only on treatment with a combination of AzaþTSA. MLECs were cultured to conﬂue
either AzaþTSA or 50 nmol/L Aza alone or 25 nmol/L TSA alone for 24 hours. Afte
Western blot is shown. b-actin was used as a loading control. Protein quantiﬁcat
control nonstimulated group was used as a standard (1 arbitrary unit) to compare
of three replicate experiments (B and C). *P < 0.01 LPS versus LPSþAzaþTSA. Or
LPS; T, TSA; TRITC, tetramethylrhodamine isothiocyanate.
The American Journal of Pathology - ajp.amjpathol.orgMLECs. Moreover, in the AJ, VE-cadherin showed an un-
even, discontinuous, or patchy pattern with small spaces in
between the cell borders (Figure 4A). However, AzaþTSA-
treated cells displayed cell borders with jagged or zigzag
appearance and more prominent AJs similar to unstimulated
control cells (Figure 4A). In addition, we observed reduced
mRNA and protein expressions of VE-cadherin in MLECs
exposed to LPS, which was signiﬁcantly restored on treat-
ment with a combination of AzaþTSA rather than either
Aza or TSA alone (P < 0.01) (Figure 4, B and C).
We observed an increase in the number of transcripts for
VE-cadherin in LPS-challenged MLECs treated with
AzaþTSA rather than the baseline control. In contrast, the
VE-cadherin protein levels in the AzaþTSA-treated
MLECs returned to baseline level similar to the control
cells. This may be due to an increased rate of transcription
but moderate level of translation in AzaþTSA-treated cells.
In addition, it was not necessary that all of the transcripts be
translated into protein within the observed period (P< 0.01)
(Figure 4, B and C).egrity. MLECs were cultured to conﬂuence and stimulated with LPS, followed
presentative confocal micrographs of TRITC-labeled VE-cadherin and FITC-
ows an uneven, discontinuous, or patchy pattern with small spaces in be-
þTSA restores the loss of VE-cadherin expression and displays cell borders
d control cells. B: RT-qPCR shows that the mRNA expression of VE-cadherin
e or TSA alone for 24 hours. Fold expression was calculated as the ratio of
VE-cadherin in MLECs exposed to LPS decreases and is signiﬁcantly restored
nce and stimulated with LPS, followed by treatment with optimal dosage of
r treatment, cells were harvested for Western blot analysis; a representative
ion was assessed by densitometry (n Z 3). The density of proteins in the
the relative density of the other groups. Data are expressed as means  SEM
iginal magniﬁcation: 600 (A). A, Aza; FITC, ﬂuorescein isothiocyanate; L,
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Thangavel et alStudies have shown that stimulation of endothelial cells
with LPS induces eNOS activation and nitric oxide pro-
duction. Activated Cav1 is known to provide a favorable
conﬁrmation for eNOS binding and inhibition of eNOS
activity and thereby maintains AJ stability.26,28,29 Studies
also indicated that Cav-1 phosphorylation enhanced binding
between phospho-Cav-1 and eNOS, which was associated
with a decrease in eNOS activity.26,29 To address the sig-
niﬁcance of the eNOS-Cav1-MLC2 cascade in AzaþTSA-
mediated AJ stabilization, we conducted a Western blot
analysis of LPS-treated MLECs. The Western blot analysis
showed an increase in levels of phosphorylated eNOS and
MLC2 (Figure 5, A and C) and a decrease in phosphorylated
Cav1 (Figure 5B). Both these changes were signiﬁcantly
reversed on treatment with AzaþTSA (P < 0.01) (Figure 5,
A and B). To further validate the signiﬁcance of the above
cascade, we next inhibited eNOS by using L-NAME. We
observed that the LPS-induced phosphorylation of eNOS
was inhibited by the treatment with L-NAME (P < 0.01)
(Figure 5D), whereas the treatment with AzaþTSA had no
effect, further conﬁrming that AzaþTSA acts through acti-
vated eNOS. In contrast, the phosphorylation of MLC2 did
not show any reduction. This lack of reduction was probably
due to the activation of MLC2 by a parallel eNOS-inde-
pendent LPS-induced pathway, which was targeted by the
drug treatment.39 Future experiments are warranted to
further delineate this pathway and its role in lung vascular
injury. Furthermore, the reduced phosphorylation of eNOS
and MLC2 by LPS-induced AzaþTSA treatment effect was
blunted on treatment with L-NAME. In addition, the LPS-
induced inhibition of Cav1 phosphorylation was signiﬁ-
cantly increased by treatment with AzaþTSA (P < 0.01),
which was reduced on treatment with L-NAME (Figure 5D).
This ﬁnding supports the previous study wherein
L-NAMEemediated inhibition of eNOS phosphorylationFigure 5 AzaþTSA treatment targets eNOS-Cav1-MLC2 signaling in endothelial
treatment with optimal dosage of either AzaþTSA or 50 nmol/L Aza alone or 25 nmo
blot analysis; representative Western blots are shown. AzaþTSA treatment reduces
reduces phosphorylation of MLC2 in MLECs exposed to LPS and treated with Aza and
by the treatment with L-NAME, whereas the phosphorylation of MLC2 does not show
phosphorylation of eNOS and MLEC2. This effect is blunted by L-NAME treatment. The
treatment with AzaþTSA. This increase is reduced on treatment with L-NAME. Tot
tiﬁcation was assessed by densitometry shown at the bottom of each blot. Data are
LPSþAza (A); yP < 0.05 LPS versus LPSþAza and LPSþTSA, zP < 0.01 LPS versus
versus LPSþAzaþTSA (C); yP< 0.05 LPSþAzaþTSA versus LNþLPSþAzaþTSA, zP<
TSA; LN, L-NAME.
2244resulted in reduced phospho-Cav1 levels, thereby promoting
uncoupling of the eNOS/Cav1 complex and disintegration
of the integrity of the endothelial junction.26 Thus, we
suggest that an AzaþTSA-dependent activated Cav1-
negative feedback mechanism that returns eNOS activity
to its ground state may be pathophysiologically important in
vascular inﬂammation, which is often associated with dys-
regulated eNOS activity, persistent NO production, and NO
modiﬁcation of endothelial regulatory proteins. Together,
these data indicate that AzaþTSA preserves the endothelial
barrier integrity partly mediated by an eNOS-Cav1-MLC2-
dependent mechanism.
Acetylation and Methylation of VE-Cadherin Promoter
Region Histone 3 in LPS-Challenged Endothelial Cells
Treated with AzaþTSA
Posttranslational modiﬁcations of histone N-terminal tails are
dynamic and essential components in the epigenetic regula-
tion of genes.40 To address the posttranslational modiﬁca-
tions of histones associated with the promoter region of
VE-cadherin in restoring the microvascular endothelial bar-
rier function and AJ integrity during ALI, MLECs were
cultured to conﬂuence and stimulated with LPS, followed by
treatment with either AzaþTSA or Aza alone or TSA alone
for 24 hours. The cells were then analyzed for altered acet-
ylation and methylation signatures of histone proteins in the
promoter region of VE-cadherin by using ChIP after induc-
tion of protection.34,35 AceH3K9, aceH3K18, and me2H3K9
active proteins at the histone tail region of VE-cadherin
promoter were less acetylated in LPS-induced MLECs
and signiﬁcantly more increased in cells treated with
AzaþTSA (P< 0.001 versus LPS and P< 0.01 versus TSA)
than in cells treated with either Aza alone or TSA alone
(P< 0.05 versus LPS) (Figure 6). Further, the treatment withcells. MLECs were cultured to conﬂuence and stimulated with LPS, followed by
l/L TSA alone for 24 hours. After treatment, cells were harvested for Western
phospho-eNOS (Ser-1167) (A), increases phosphorylation of Cav1 (B), and
TSA cultured for 30 minutes (C). D: The phosphorylation of eNOS is inhibited
any reduction. LPS-induced MLECs treated with AzaþTSA show reduction in
LPS-induced inhibition of Cav1 phosphorylation is signiﬁcantly increased by
al eNOS, Cav1, and total MLC2 were used as loading controls. Protein quan-
expressed as means SEM. nZ 3. *P< 0.05 LPS versus LPSþAzaþTSA and
LPSþAzaþTSA (B); *P < 0.05 versus LPSþAza and LPSþTSA, yP < 0.01 LPS
0.01 LPS versus LNþLPS and LPS versus LPSþAzaþTSA (D). A, Aza; L, LPS; T,
ajp.amjpathol.org - The American Journal of Pathology
Figure 7 AzaþTSA treatment increases survival in LPS-challenged mice.
A: Survival trend of normal mice (blue) or LPS (40 mg/kg, i.p.; red) injected
mice in the presence of either no drug treatment, single modality 1 hour
before therapy Aza alone (4.4 mmol/L/kg, i.p.; green), TSA alone (3.3
mmol/L/kg, i.p.; purple), or combination of AzaþTSA regimen (blue) up to
2 weeks. For histological, molecular, and immunological analyses, mice
injected with 10 mg/kg LPS were treated with 4.4 mmol/L/kg Aza alone, 3.3
mmol/L/kg TSA alone, or AzaþTSA. The lung tissues and blood were
collected on day 2. B: Representative microscopic images of lung tissue
sections. C: The quantitative results for neutrophil inﬁltration. n Z 5 (A;
Aza alone, TSA alone, and AzaþTSA). yP < 0.01 versus LPS (A); *P < 0.05
LPS versus LPS þ TSA (C); *P < 0.05 LPSþTSA versus LPSþAzaþTSA (C);
yP < 0.01 LPS and LPSþAza versus LPSþAzaþTSA (C). Original magniﬁ-
cation: 400 (B). A, Aza; L, LPS; T, TSA.
Figure 6 Epigenetic mechanism of restoring microvascular endothelial
barrier function. MLECs were cultured and stimulated with LPS, followed by
treatment with an optimal dose of either AzaþTSA or Aza alone or TSA alone
for 24 hours. Then the cells were analyzed for altered acetylation and
methylation signatures on histone proteins involved at the VE-cadherin
promoter during induction of protection by ChIP with the use of anti-
bodies of aceH3K9, aceH3K18, and me2H3K9 or anti-IgG control antibody.
A: Acetylation and methylation status of histone H3 shows that VE-cadherin
promoter is closely related to control cells and more highly acetylated and
methylated in LPS-induced MLECs treated with AzaþTSA than in MLECs
treated with Aza or TSA alone. B: Quantiﬁcation of ChIP assay. Data are
expressed as means SEM. nZ 3. *P< 0.05 LPS versus LPSþTSA; yP< 0.01
LPS versus LPSþAzaþTSA; zP < 0.05 LPSþTSA versus LPSþAzaþTSA.
Attenuation of Lung HyperpermeabilityAzaþTSA had a signiﬁcantly greater effect on the acetylation
and methylation status of histone 3 than treatment with Aza
or TSA alone at the VE-cadherin gene promoter in LPS-
induced MLECs (Figure 6, A and B).
AzaþTSA Treatment Reduces LPS-Induced Mortality
ALI was induced in C57BL/6J mice by intraperitoneal in-
jection of LPS (lethal dose of 40 mg/kg BW). One hour after
LPS administration, mice were treated intraperitoneally either
with vehicle or 4.4 mmol/L/kg BWAza or 3.3 mmol/L/kg BWThe American Journal of Pathology - ajp.amjpathol.orgTSA or combination of AzaþTSA. Survival was monitored
for 14 days, and histological changes and gene expression
were evaluated in the lung at different times. All of the mice in
the control group subjected to LPS died in <19 hours (0%
survival), whereas mice treated with Aza died within 24
hours. The mice treated with TSA alone exhibited only a 20%
survival rate, whereas mice in the AzaþTSA-treated group
displayed a strikingly higher survival rate of 80% and had a
prolonged survival time during the observed period of 14 days
(P < 0.01) (Figure 7A). These data strongly support a ther-
apeutic potential of epigenetic modiﬁers during endotoxemia.
On day 2, immunohistochemical staining of neutrophil-
speciﬁc antibody Ly-6G6C on lung tissues showed a
consistently reduced LPS-induced neutrophil recruitment
into the airspace after a sublethal dose of LPS in mice treated
with AzaþTSA compared with mice untreated and treated
with Aza alone or TSA alone (Figure 7, B and C). Lung
myeloperoxidase content is a well-established indicator of2245
Figure 8 AzaþTSA treatment decreases number of apoptotic cells in lungs after LPS
challenge. A: The apoptosis assay was performed with TUNEL on lung tissue collected from
mice exposed to a sublethal dosage of LPS and treated with AzaþTSA or either Aza alone or
TSA alone on day 6. Cell death was assessed by TUNEL staining. The TUNELþ cells were
assessed by counting the number of double-positive cells (pink) as a result of colocali-
zation of TUNEL (red) and DAPI (blue). B: Quantiﬁcation of double-positive apoptotic
cells. Lung tissues in mice treated with AzaþTSA show fewer TUNELþ cells compared with
the LPS-induced control group and cells treated with either Aza alone or TSA alone. Data
are expressed as means  SEM (B). n Z 3. *P < 0.05 LPSþTSA versus LPSþAzaþTSA;
yP < 0.01 LPS and LPSþAza versus LPSþAzaþTSA. A, Aza; L, LPS; T, TSA.
Thangavel et alneutrophilic sequestration in lung injury. Myeloperoxidase
content was signiﬁcantly more reduced in mice treated with
AzaþTSA than in untreated mice (P < 0.01) (Supplemental
Figure S3A). We also found signiﬁcantly more decreased
TNFa and IL-8 gene expressions in LPS-induced lungs
treated with AzaþTSA than in lungs treated with either
Aza or TSA alone (TNFa, P < 0.01; IL8, P < 0.001)
(Supplemental Figure S3, B and C).
AzaþTSA-Treated Mice Show Decreased Apoptotic Cell
Numbers in Lungs
In addition, to assess apoptosis, we performed TUNEL
assay staining on day 6 on the superior lobe of lung tissues
from mice induced with sublethal dose of LPS and treated
with AzaþTSA. We examined the sections by immunoﬂu-
orescence microscopy. Cell death was assessed by colo-
calized double positivity of TUNEL-red and DAPI-blue
(pink) (Figure 8A). The number of apoptotic cells was
signiﬁcantly lower in the AzaþTSA-treated group than in
groups treated with either Aza alone or TSA alone
(P < 0.01 LPS versus LPSþAzaþTSA) (Figure 8B).
Discussion
Sepsis-induced ALI is a clinical condition common in the
intensive care setting, with poor outcomes for which no2246deﬁnitive therapies are currently available. The molecular
mechanisms that regulate lung endothelial barrier repair after
lung vascular injury, a primary cause of ALI from sepsis after
lung injury, remain incompletely understood. This is the ﬁrst
study to examine the efﬁcacy of a combinatorial treatment
with epigenetic-modifying agents AzaþTSA on lung endo-
thelial barrier function after sepsis. Our data show that
treatment with a single dose of AzaþTSA in a mouse model
of ALI prevented lung vascular hyperpermeability and in-
ﬂammatory lung injury and promoted survival rate that
compared with treatment with either Aza or TSA alone.
Mechanistically, AzaþTSA treatment suppressed phos-
phorylation of MLC2 and eNOS and activated Cav1.
The above effects are attributed to AzaþTSA-mediated
epigenetic modulation of acetylated and methylated histone
3 protein of the VE-cadherin promoter.
Although epigenetic modiﬁers were shown to attenuate the
generation of inﬂammatory cytokines and chemokines and
inﬂammatory injury in the airway, digestive tract, and joints in
animal models, the results have been variable.41e44 This
variability may be because previous studies examined the ef-
fects of pretreatment with HDAC inhibitors and other epige-
netic modiﬁers rather than studying their value in therapeutic
protocols. Agents such as TSA are chemotherapeutic agents
that induce differentiation and promote apoptosis in trans-
formed cells at higher concentrations.45 TSA also suppressed
the production of inﬂammatory cytokines in animal models ofajp.amjpathol.org - The American Journal of Pathology
Figure 9 Schematic representation of pro-
posed molecular mechanisms. LPS induces
expression of VE-cadherin by eNOS-caveolin-MLC2
signaling mechanism in lung endothelial cells. In
addition, LPS reduces acetylation and methylation
of histone 3 tail (lysine residues 9 and 18) on VE-
cadherin promoter. Epigenetic modiﬁers Aza þ
TSA function by inhibiting activation of eNOS-
caveolin-MLC2 signaling and alterations in acety-
lation and methylation in VE-cadherin promoter,
and thus restore the loss of integrity of AJs. A,
Aza; T, TSA; TLR, Toll-like receptor.
Attenuation of Lung Hyperpermeabilityautoimmune and inﬂammatory disease.41,46,47 Our observa-
tions showed that treatment with nanomolar concentrations of
Aza and TSA had no suppressive effect on cell viability;
rather, both agents enhanced cell proliferation. Our data also
showed that AzaþTSA treatment signiﬁcantly reduced LPS-
induced apoptosis of lung endothelial cells and enhanced
cell survival. Studies showed that endothelial cells play a
central role in pulmonary vascular hyperpermeability and
consequent edema formation after inﬂammatory lung injury.38
Our data indicate that combinatorial AzaþTSA therapy in
nanomolar concentrations prevented these changes, and both
drugs together were more efﬁcacious than either drug alone. In
this study, we used different dosages of AzaþTSA and LPS
for the in vivo and in vitro experiments. In our survival study,
we used a lethal dose of 40mg/kg BW, and for all other in vivo
experiments we used 10 mg/kg BW so that we could collect
tissues from all groups of animals on day 2 and 6. We used 1
mg/mLLPS for the in vitro culture system, which is 1000 times
less than the concentration used in the in vivo system. In vitro-
based experiments are unable to withstand concentrations of
the drugs used for in vivo studies. Hence, there is a greater
likelihood of diminished cell viability and inconsistent results.
Whereas, in in vivo experiments, despite higher drug con-
centrations, direct cell toxicity is limited because of the phar-
macokinetics of the drug.
eNOS inhibitors prevented the increase in lung vascular
permeability observed in Cav1-deﬁcient mice, consistent with
the essential role of eNOS activity and NO generation in the
mechanism of increased permeability.48 Activated (phos-
phorylated) eNOS in endothelial cells induced nitration of
p190RhoGAP and concomitantly activated RhoA, resulting in
cytoskeleton reorganization with increased contractility from
increased phospho-MLC levels and retraction of VE-cadherin
AJs.29 This ﬁnding provides a causal link between eNOS andThe American Journal of Pathology - ajp.amjpathol.orgdisruption of the vascular endothelial barrier.29 Our present
data show that lung endothelial cells exposed to LPS showed a
signiﬁcant decrease in TER, which was ameliorated by treat-
ment with AzaþTSA. These ﬁndings were conﬁrmed in the
mouse lung experiments that showed signiﬁcantly increased
lung vascular ﬁltration coefﬁcient in LPS-exposed untreated
cells, which was also signiﬁcantly reduced inmice treated with
AzaþTSA.
We observed a reduction in expression of VE-cadherin in
lung endothelial cells exposed to LPS, which was prevented
with AzaþTSA treatment. The defect in VE-cadherin was
partly mediated though eNOS-Cav1-MLC2edependent
signaling, and AzaþTSA treatment seemed to function at
the level of this pathway. Thus, these epigenetic modifying
agents attenuated the dissociation of VE-cadherin junctions
and endothelial junctional permeability.
Epigenetic modiﬁers produce epigenetic changes, with ef-
fects that are apparently reversible. The changes lead to
modiﬁcations of DNA or chromatin, which do not involve
alterations in DNA sequence.8,49 Severe inﬂammation was
shown to be associated with HDAC/histone acetyltransferase
imbalance, which inﬂuences the acetylation status of histones
in lungs and heart.50 Here, we addressed the possibility that
gene expression in endothelial cells after LPS exposure is
regulated by histone modiﬁcations. Previous studies showed
increased levels of dimethyl histone 3 lysine 9 and trimethyl
histone 3 lysine 27 and reduced acetylation of acetylated his-
tone 3 lysine 18 and acetylated histone 3 lysine 27, which are
characteristics of heterochromatin and euchromatin, respec-
tively.51 We examined the status of these histone markers in
the promoter region of the VE-cadherin gene. ChIP analysis
showed reduced acetylation of active histone proteins
aceH3K9 and aceH3K18 in VE-cadherin promoter in LPS-
challenged endothelial cells, and treatment of cells with2247
Thangavel et alAzaþTSA increased acetylation. Further, we observed
reduced methylation of another active histone protein,
me2H3K9, in VE-cadherin promoter in LPS-challenged
endothelial cells, which was increased on treatment with
AzaþTSA. These data suggest that the endothelial barrier
protective effect of treating with combination of AzaþTSA is
the result of acetylation and methylation modiﬁcations of
histone at the level of VE-cadherin promoter.
Mortality studies after 14 days of follow-up found a signif-
icantly greater survival rate (80%) in AzaþTSA-treated mice
than in control mice. LPS-induced inﬁltration of neutrophils
and generation of inﬂammatory cytokines in lung tissues were
also signiﬁcantly reduced in AzaþTSA-treated mice. Mice
treated with either Aza or TSA exhibitedmortality similar to the
untreated LPS-challenged group, with death commencing as
early as within the ﬁrst 24 hours of treatment. These ﬁndings
further highlight the therapeutic potential of AzaþTSA.
In conclusion, a single dose of AzaþTSA administered after
onset of ALI attenuated lung vascular hyperpermeability and
inﬂammatory lung injury. The molecular mechanisms under-
lying the protective action of AzaþTSA involvedmodiﬁcation
of histone acetylation and methylation at the level of VE-
cadherin promoter and reduced phosphorylation of eNOS and
MLC2 and increased phosphorylation of Cav1 (Figure 9).
Together, these observations identify a novel approach that
uses epigenetic modifying agents to reverse the outcome of
ALI induced by endotoxemia.Acknowledgment
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